SEARCH

SEARCH BY CITATION

References

  • 1
    Kalogeropoulos AP, Georgiopoulou VV, Butler J. Clinical adoption of prognostic biomarkers: the case for heart failure. Prog Cardiovasc Dis. 2012;55:313.
  • 2
    Tang WHW, Francis GS, Morrow DA, et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation. 2007;116:e99109.
  • 3
    Cole RT, Masoumi A, Triposkiadis F, et al. Renal dysfunction in heart failure. Med Clin North Am. 2012;96:955974.
  • 4
    Butler J, Chirovsky D, Phatak H, et al. Renal function, health outcomes, and resource utilization in acute heart failure: a systematic review. Circ Heart Fail. 2010;3:726745.
  • 5
    Kim H, Yoon HJ, Park HS, et al. The potentials of cystatin C and uric acid for predicting prognosis of heart failure. Congest Heart Fail. 2012;DOI: 10.1111/chf.12012 [Epub ahead of print].
  • 6
    Manzano-Fernandez S, Januzzi JL Jr, Boronat-Garcia M, et al. beta-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure. J Am Coll Cardiol. 2011;57:849858.
  • 7
    Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation. 2010;122:173183.
  • 8
    Ky B, French B, Levy WC, et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail. 2012;5:183190.
  • 9
    Butler J, Kalogeropoulos A. Hospital strategies to reduce heart failure readmissions: where is the evidence? J Am Coll Cardiol. 2012;60:615617.
  • 10
    Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105:26192624.
  • 11
    Hare JM, Johnson RJ. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation. 2003;107:951953.
  • 12
    Farquharson CA, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106:221226.
  • 13
    Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104:24072411.
  • 14
    Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008;51:23012309.
  • 15
    Using allopurinol to relieve symptoms in patients with heart failure and high uric acid levels (EXACT-HF). http://www.clinicaltrials.gov/ct2/show/NCT00987415. Accessed October 19, 2012.
  • 16
    Hirsch GA, Bottomley PA, Gerstenblith G, Weiss RG. Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts. J Am Coll Cardiol. 2012;59:802808.